MedPath

Tianjin Medical University Cancer Institute & Hospital

🇨🇳China
Ownership
-
Employees
-
Market Cap
-
Website

Endostar Combined With Chemotherapy for Stage Ⅳ Soft Tissue Sarcoma

Phase 2
Completed
Conditions
Soft Tissue Sarcoma, Adult, Stage IIB
Interventions
Drug: Placebo
Drug: AIM regimen / GT regimen
First Posted Date
2017-04-20
Last Posted Date
2019-12-26
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
52
Registration Number
NCT03121833
Locations
🇨🇳

Tianjin Medical University Cancer Hospital & Institute, Tianjin, Tianjin, China

Mesylate Apatinib for Stage Ⅳ STS After Failure of Chemotherapy

Phase 2
Conditions
Soft Tissue Sarcoma, Adult, Stage II
Interventions
First Posted Date
2017-04-20
Last Posted Date
2017-05-22
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
80
Registration Number
NCT03121846
Locations
🇨🇳

Tianjin Medical University Cancer Hospital & Institute, Tianjin, Tianjin, China

The Exploratory Study of Electroacupuncture in the Treatment of Peripheral Neuropathy Induced by Platinum Based Chemotherapy Drugs

Not Applicable
Conditions
Chemotherapy-induced Peripheral Neuropathy
Interventions
Device: electroacupuncture
First Posted Date
2017-02-09
Last Posted Date
2018-02-12
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
72
Registration Number
NCT03048591

Study of Apatinib in Advanced Hepatocellular Carcinoma(HCC)

Phase 2
Conditions
Hepatocellular Carcinoma
Interventions
First Posted Date
2017-02-08
Last Posted Date
2017-02-08
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
30
Registration Number
NCT03046979
Locations
🇨🇳

Tianjin Medical University Cancer Institute and Hospital, Tianjin, China

Evaluation of Pcv-aCO2 in the Fluid Treatment of Abdominal Tumor Patients After Surgery

Not Applicable
Conditions
Abdominal Tumor
Abdominal Infection
Interventions
Other: conventional fluid therapy
Other: standardized fluid therapy
First Posted Date
2016-11-30
Last Posted Date
2016-11-30
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
150
Registration Number
NCT02977429
Locations
🇨🇳

Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China

A Phase II Trial to Compare Efficacy and Safety of CRT VS Neo-CRT in Patients Who Achieved CCR for Esophageal Cancer

Phase 2
Conditions
Stage III Esophageal Cancer
Stage II Esophageal Cancer
Interventions
Radiation: Definitive Radiochemotherapy
Procedure: Neoadjuvant Radiochemotherapy
First Posted Date
2016-11-09
Last Posted Date
2017-07-18
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
40
Registration Number
NCT02959385
Locations
🇨🇳

Department of Radiation Oncology, Tianjin Medical University Cancer Hospital, Tianjin, Tianjin, China

Regulation of LncRNA For Breg in Patients With Thymoma and Autoimmune Diseases

Withdrawn
Conditions
Thymoma
Autoimmune Disease
First Posted Date
2016-10-31
Last Posted Date
2018-05-18
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Registration Number
NCT02948855
Locations
🇨🇳

Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China

Effect of Different Anesthetics on the Change of Alarmins in Lung Cancer Patients Receiving Pulmonary Lobectomy

Not Applicable
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
First Posted Date
2016-09-27
Last Posted Date
2016-09-27
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
40
Registration Number
NCT02916147

A One-Arm Exploratory Clinical Trial of Apatinib Plus Gemcitabine in Patients With Advanced Metastatic Pancreatic Cancer

Phase 2
Conditions
Metastatic Pancreatic Cancer
Interventions
First Posted Date
2016-08-11
Last Posted Date
2016-08-11
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
30
Registration Number
NCT02863367

Retrospective Analysis of Effectiveness and Safety Profile of Anastrozole and Letrozole in HR+ Breast Cancer Patients

Conditions
Breast Cancer
First Posted Date
2016-06-24
Last Posted Date
2016-06-24
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
1000
Registration Number
NCT02812277
© Copyright 2025. All Rights Reserved by MedPath